Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06863545
NA

Further Lipid-Lowering With PCSK9 Inhibitors for Cardiovascular Outcomes in High-Risk Coronary Plaques Assessed by CT Angiography

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

View on ClinicalTrials.gov

Summary

The primary objective was to evaluate the effect of PCSK9 inhibitors in addition to the background lipid-modifying therapy (LMT), compared with standard LMT in terms of clinical outcomes in patients with coronary CT angiography (CCTA)-detected high-risk plaques.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

3596

Start Date

2025-04-22

Completion Date

2033-04

Last Updated

2026-02-06

Healthy Volunteers

No

Interventions

DRUG

PCSK9 inhibitors and background lipid-modifying therapy

Patients will receive subcutaneous injections of PCSK9 inhibitors and oral administration of background LMT (including statins and/or cholesterol absorption inhibitors) for the first 12 months after randomization, with PCSK9 inhibitors administered every 2 weeks. After the first 12 months, patients will discontinue the PCSK9 inhibitors but continue background LMT for the remainder of the trial.

DRUG

Standard lipid-modifying therapy

Patients will receive standard LMT commonly used in clinical practice.

Locations (6)

Zhejiang Provincial Hospital of Traditional Chinese Medicine

Hangzhou, Zhejiang, China

Hangzhou Linping First People's Hospital

Hangzhou, China

The Second Affiliated Hospital, School of Medicine, Zhejiang University

Hangzhou, China

Zhejiang Hospital

Hangzhou, China

Jinhua Central Hospital

Jinhua, China

Seoul National University Hospital

Seoul, South Korea